Geron Corporation heads into its Q1 2026 earnings release today with short sellers stubbornly entrenched — and options traders turning sharply more defensive at the last minute.
Short interest is genuinely elevated at nearly 12% of the free float, and it has climbed about 15% over the past month. The week-over-week increase has been steady, with shares short creeping from ~65 million in late April to more than 75 million now — a meaningful build heading into the print. Despite that, the lending market tells a looser story: borrow availability is running at over 1,100% of short interest, and the cost to borrow has barely moved, holding near 0.5%. Short sellers are not under pressure; adding to a position remains easy.
The options signal is harder to ignore. The put/call ratio jumped to 0.52 on Wednesday — more than four standard deviations above its 20-day average of 0.45. That is the most defensive the options market has been for Geron in the past year, barring a single outlier spike. The timing is pointed: the ratio had been almost perfectly flat for six straight weeks before this sudden move. One session prior to earnings, someone was paying for downside protection. The stock itself closed at $1.58, down 4.2% on the day, though it had recovered about 4.6% across the week — leaving it still roughly 5% lower on the month.
The analyst community is divided, though the most recent substantive moves all point the same direction. Across 2025, Stifel, Barclays, and Scotiabank all cut targets — in some cases by more than half — while maintaining constructive ratings, a signal that conviction has softened even among bulls. The bull case rests on imetelstat's EU approval for low-risk myelodysplastic syndrome and the prospect of revenue diversification beyond third-line therapies in the US. Bears point to flat near-term revenues, the postponement of IMpactMF trial readouts to the second half of 2026, and the absence of any near-term catalyst to change the commercial trajectory. One historical datapoint frames the stakes: after the February 2026 print, fell 2.3% on the day and slid 17% over the following five sessions — the most recent reminder of how harshly the market can punish a disappointing update at these price levels.
Today's print is ultimately a test of whether Rytelo's commercial ramp is generating enough momentum to reframe the narrative — or whether the company is still in a holding pattern waiting for trial data that won't arrive until year-end.
See the live data behind this article on ORTEX.
Open GERN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
